Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2025 Feb 21:2024.10.16.618717.
doi: 10.1101/2024.10.16.618717.

Decoding m6Am by simultaneous transcription-start mapping and methylation quantification

Affiliations
Free PMC article

Decoding m6Am by simultaneous transcription-start mapping and methylation quantification

Jianheng Fox Liu et al. bioRxiv. .
Free PMC article

Update in

Abstract

N 6,2'-O-dimethyladenosine (m6Am) is a modified nucleotide located at the first transcribed position in mRNA and snRNA that is essential for diverse physiological processes. m6Am mapping methods assume each gene uses a single start nucleotide. However, gene transcription usually involves multiple start sites, generating numerous 5' isoforms. Thus, gene levels annotations cannot capture the diversity of m6Am modification in the transcriptome. Here we describe CROWN-seq, which simultaneously identifies transcription-start nucleotides and quantifies m6Am stoichiometry for each 5' isoform that initiates with adenosine. Using CROWN-seq, we map the m6Am landscape in nine human cell lines. Our findings reveal that m6Am is nearly always a high stoichiometry modification, with only a small subset of cellular mRNAs showing lower m6Am stoichiometry. We find that m6Am is associated with increased transcript expression and provide evidence that m6Am may be linked to transcription initiation associated with specific promoter sequences and initiation mechanisms. These data suggest a potential new function for m6Am in influencing transcription.

PubMed Disclaimer

Conflict of interest statement

S.R.J is a scientific founder of, advisor to, and/or owns equity in Chimerna Therapeutics, Lucerna Technologies, and 858 Therapeutics.

References

    1. Bioinformatics. 2011 Apr 1;27(7):1017-8 - PubMed
    1. Curr Protoc Hum Genet. 2012 Apr;Chapter 11:11.12.1-11.12.10 - PubMed
    1. J Am Chem Soc. 2020 Oct 14;142(41):17766-17781 - PubMed
    1. Mol Cell. 2023 Apr 20;83(8):1264-1279.e10 - PubMed
    1. Sci Data. 2017 Aug 29;4:170112 - PubMed

Publication types